Product Description
Chong Kun Dang was developing ckd-397, an oral ADRA1A agonist,PDE5 Inhibitor, for the treatment of Benign Prostatic Hypertrophy (BPH) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02615782)
Mechanisms of Action: ADRA1A agonist, PDE5 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostatic Hyperplasia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02615782 |
150FDI15031 | P1 |
Completed |
Prostatic Hyperplasia |
2016-04-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|